Question for the board......
For the last several months, like many, I was looking at CLSN as a binary event company. If the trial results were positive, we would make money but if they were not, we would not.
This morning on IHUB...buc posted the following:
One Hour Meeting Turned Into "Half A Day
Here is a little quote people seem to have forgotten from the Q3 CC
I and Dr. [Reed] met for almost half a day with the Chinese FDA Center for Drug Evaluation & Research or CDER. The meeting frankly was planned to be for just a little over an hour and we spent almost half a day. The outcome was positive, more than positive. That said, they will accept an NDA filing without the need for a reference country approval. This might be a first.
This is big big news. Since China is a huuuge market for TDOX-- even IF the US/FDA passes on Tdox(and that's not likely) , then Celsion can still make big money in the Chinese market. So much for the theory that CLSN goes to $1 on sub par data. With China still in play, the share price should hit a bottom of $3-4, I think. And if the data is good??? Then you better pray that you're not short...
Exactly. FDA approval in the U.S. is less relevant. Chinese approval and revenues in 2013.
Wonder if they have a lower than 33% threshold.
Then Kris kade follows up with the following:
Also if you read my earlier post, the agreement with Hisun specifically mandates for the HEAT trial to be positive which means only one thing:
33% or greater and we are off to the races for both US FDA and China sFDA.........
If you agree with these comments, which I do, then we need to see only a small improvement in the trial (33%) to be considered positive and we will have the China market regardless of what happens in the US market. This means our chances for success are now significantly greater with this Hisun agreement.
Do you folks agree with this assessment? TIA
